Overview: FGF14 TestIntroduction: The FGF14 Test tests for FGF14 gene mutations to diagnose spinocerebellar ataxia, causing coordination problems or tremors, aiding in genetic diagnosis. Affecting 1 in 100,000 people, spinocerebellar ataxia poses diagnostic challenges due to its progressive nature. Following 2023 American College of Medical Genetics (ACMG) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, genetic counseling, and improving outcomes in neurology.
Other Names: FGF14 Mutation Test, SCA Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Genetic testing for ataxia began in the 1990s with research by Zoghbi, who mapped ataxia genes. PCR/sequencing advancements in the 2000s by Illumina improved detection, surpassing earlier linkage analysis methods.
Purpose: Detects FGF14 mutations to diagnose spinocerebellar ataxia, guides supportive therapy, and evaluates patients with coordination issues, aiming to manage symptoms.
Test Parameters: FGF14 gene mutations
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of neurological issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document coordination issues or tremors. Include current medications or family history of genetic disorders.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., disability), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutations confirm ataxia, guiding therapy. Early diagnosis might improve management, while untreated cases lead to worsening. Normal results may require MRI.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: Brain imaging, EMG, or genetic panel to confirm diagnosis.
Test Limitations: Specific to FGF14 gene; correlation with symptoms needed. False negatives possible with untested variants.
References: ACMG Guidelines, 2023; Neurology, Zoghbi HY, 2022.
